Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya
Authors: Gaby Isabelle Ooms, Janneke van Oirschot, Dorothy Okemo, Benjamin Waldmann, Eugene Erulu, Aukje K Mantel-Teeuwisse, Hendrika A van den Ham, Tim Reed
Journal: PLOS Neglected Tropical Diseases
Accepted: 2021-08-03T00:00:00Z

Background: Annually, about 2.7 million snakebite envenomings occur globally. Alongside antivenom, patients usually require additional care to treat envenoming symptoms and antivenom side effects. Efforts are underway to improve snakebite care, but evidence from the ground to inform this is scarce. This study, therefore, investigated the availability, affordability, and stock-outs of antivenom and commodities for supportive snakebite care in health facilities across Kenya. Methodology/principal findings: This study used an adaptation of the standardised World Health Organization (WHO)/Health Action International methodology. Data on commodity availability, prices and stock-outs were collected in July-August 2020 from public (n = 85), private (n = 36), and private not-for-profit (n = 12) facilities in Kenya. Stock-outs were measured retrospectively for a twelve-month period, enabling a comparison of a pre-COVID-19 period to stock-outs during COVID-19. Affordability was calculated using the wage of a lowest-paid government worker (LPGW) and the impoverishment approach. Accessibility was assessed combining the WHO availability target (≥80%) and LPGW affordability (<1 day’s wage) measures. Overall availability of snakebite commodities was low (43.0%). Antivenom was available at 44.7% of public- and 19.4% of private facilities. Stock-outs of any snakebite commodity were common in the public- (18.6%) and private (11.7%) sectors, and had worsened during COVID-19 (10.6% versus 17.0% public sector, 8.4% versus 11.7% private sector). Affordability was not an issue in the public sector, while in the private sector the median cost of one vial of antivenom was 14.4 days’ wage for an LPGW. Five commodities in the public sector and two in the private sector were deemed accessible. Conclusions: Access to snakebite care is problematic in Kenya and seemed to have worsened during COVID-19. To improve access, efforts should focus on ensuring availability at both lower- and higher-level facilities, and improving the supply chain to reduce stock-outs. Including antivenom into Universal Health Coverage benefits packages would further facilitate accessibility. Author summary: Annually, about 2.7 million snakebite envenomings occur globally. Treatment requires the use of antivenom, and often additional care to treat envenoming symptoms or side effects of antivenom use is also needed. Considering snakebite is common in Kenya but evidence from the ground is scarce, we set out to collect data on the availability, affordability, and stock-outs of antivenom and other commodities commonly used in the treatment of snakebite. We found that overall availability of snakebite commodities was low in Kenya, with antivenom available at 45% of public facilities, and less than 20% of private facilities. The snakebite commodities were also commonly stocked out, which seemed to have worsened during the COVID-19 pandemic. Affordability was not a problem in the public sector, where commodities were free for the patient. In the private sector, especially antivenom was unaffordable. These results highlight that the biggest issue with access to snakebite care in both the public and private sectors of Kenya was related to availability of commodities. Efforts to improve access to snakebite care in Kenya should focus on ensuring availability of the commodities at both lower- and higher-level facilities, and improving the supply chain to reduce stock-outs.